Found 11 clinical trials
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)
Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …
- 0 views
- 04 Dec, 2020
- 126 locations
Genetic Characteristics of Metastatic Breast Cancer Patients
Genomic analysis for metastatic breast cancer(MBC) patients Participant (Inclusion criteria) Patients who diagnosed metastatic/stage IV breast cancer Patients who were not received treatment for metastatic breast cancer on palliative setting Process (1) Tissue/ Blood sample At diagnosis, MBC tissue / blood sample (20cc) will be obtained.
- 0 views
- 16 Feb, 2024
- 1 location
A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT)
This is a randomized clinical trial (OMIT study) evaluating the efficacy of metastasectomy in patients with oligo-metastatic breast cancer.
- 0 views
- 16 Feb, 2024
- 1 location
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
This phase III trial aims to compare the progression free survival (PFS) and safety of fulvestrant or capecitabine as maintenance therapy after first-line combined chemotherapy in hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer.
- 0 views
- 16 Feb, 2024
- 7 locations
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors harboring PIK3CA mutations, candidates to receive maintenance HP after first line …
- 0 views
- 16 Feb, 2024
- 10 locations
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
- 0 views
- 16 Feb, 2024
- 1 location
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment that included a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Venetoclax is an investigational drug being developed for the treatment of breast cancer.
- 0 views
- 16 Feb, 2024
- 16 locations
Pilot Study of the eHealth Application (CAPABLE-IT)
The purpose of the CAPABLE study is to compare health-related quality of life in renal cell carcinoma patients who use or do not use a mobile-based application to monitor adverse events for cancer treatment at home. As secondary objectives, the study investigates the usability of the system and its generalizability …
- 0 views
- 08 Dec, 2023
Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients (EEBC)
The elderly patients over 65 years old with breast cancer have concomitant diseases, poor tolerance to conventional treatment, and the specific prognosis of breast cancer is relatively good. Previous studies on breast cancer have almost excluded elderly breast cancer patients, and conventional treatment schemes cannot meet the clinical diagnosis and …
- 0 views
- 16 Jun, 2023
- 1 location
reatment Standards and Outcomes of Patients With ER/PR Positive HER2-negative Metastatic Breast Cancer
To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece
- 0 views
- 16 Feb, 2024
- 1 location
- 1
- 2